External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

BACKGROUND AND AIMS: Trastuzumab provides clinical benefit for advanced and early breast cancer patients whose tumours over‐express or have gene amplification of the HER2 oncogene. The UK National External Quality Assessment Scheme (NEQAS) for immunohistochemical testing was established to assess an...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Bartlett, John M S, Ibrahim, Merdol, Jasani, Bharat, Morgan, John M, Ellis, Ian, Kay, Elaine, Magee, Hilary, Barnett, Sarah, Miller, Keith
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Group 2007
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC1995794/
https://ncbi.nlm.nih.gov/pubmed/16963466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jcp.2006.040840
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia